NCT01849094View on ClinicalTrials.gov

Evaluating the Safety, Pharmacokinetics and Haemodynamic Effect of a Slow Release Oral Formulation of Milrinone

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
HealthyHeart Failure
Interventions
DRUG

Milrinone 6mg

Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements

DRUG

milrinone 10mg ER

Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements

DRUG

milrinone 14mg

Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements

Trial Locations (2)

3004

Alfred Hospital, Melbourne

Nucleus Network, Melbourne

All Listed Sponsors
lead

The Alfred

OTHER

NCT01849094 - Evaluating the Safety, Pharmacokinetics and Haemodynamic Effect of a Slow Release Oral Formulation of Milrinone | Biotech Hunter | Biotech Hunter